SL Science (SLBT) Reports Positive Preclinical Data for Gamma-Omega T Cells in Glioblastoma

SL Science Holding Limited (SLBT) announced positive preclinical data for its gamma-omega T cell therapy targeting glioblastoma (GBM), with results presented at the 85th Annual Meeting of the Japanese Cancer Association. The announcement was made on September 20, 2026. Glioblastoma is among the most aggressive and treatment-resistant forms of brain cancer, with limited therapeutic options and poor survival rates. The preclinical findings suggest the company's gamma-omega T cell approach may offer a viable targeting mechanism against GBM cells. The data presentation marks an early-stage milestone for SLBT's immuno-oncology pipeline. No financial terms, partnership details, or clinical trial timelines were disclosed. Further development stages and regulatory pathways remain unspecified.